On this page

Desonide

Prescription ANDA TE AB Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Desonide
Generic name
Desonide
Dosage form
Ointment
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Alembic Pharmaceuticals Limited
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
5
Packages
10
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Desonide .5 mg/g 204135 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Ointment
Route of administration
Topical
Presentations
15

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
212473
Application type
ANDA · Abbreviated New Drug Application
Approval date
October 23, 2019
Sponsor
ALEMBIC
Products on application
1
Submissions recorded
1
Products approved under application 212473.
Product Trade name Form Strength Ingredient Status TE Flags
212473-001 DESONIDE OINTMENT DESONIDE Prescription AB

Therapeutic equivalence

Source: Orange Book
TE code
AB
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 212473.
Type No. Action Status Date Review
Original application 1 Approved October 23, 2019 Standard

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260417). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260417 HUMAN PRESCRIPTION DRUG · 20230914

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Desonide ointment USP, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. It should not be used for longer than two weeks unless directed by a physician.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Desonide ointment USP, 0.05% should be applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within two weeks, reassessment of diagnosis may be necessary. Desonide ointment USP, 0.05% should not be used with occlusive dressings.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Desonide ointment USP, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS In controlled clinical trials, the total incidence of adverse reactions associated with the use of desonide ointment USP, 0.05% was approximately 6%. These adverse reactions were erythema, induration, pruritus, irritation, oiliness, and peripheral edema. The following additional local adverse reactions have been reported infrequently with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in approximate decreasing order of occurrence: dryness, folliculitis, acneiform eruptions, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, miliaria, burning and hypopigmentation. To report SUSPECTED ADVERSE REACTIONS, contact Alembic Pharmaceuticals, Inc. at 1-866-210-9797 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Description

openFDA Drug Labeling

DESCRIPTION Desonide Ointment, 0.05% contains desonide (Pregna-1,4-diene-3,20-dione,11,21-dihydroxy-16,17- [(1-methylethylidene)bis(oxy)]-,(11β,16α-)) a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primary synthetic steroids used topically as anti-inflammatory and antipruritic agents. Chemically, desonide, the active ingredient in Desonide Ointment, 0.05%, is C 24 H 32 O 6 . It has the following structural formula: The molecular weight of desonide is 416.51. It is a white to off-white odorless powder which is soluble in methanol and practically insoluble in water. Each gram of Desonide Ointment, 0.05% contains 0.5 milligram of desonide in an ointment base consisting of mineral oil and white petrolatum. It is a smooth, uniform petrolatum-type ointment. Chemical Structure

OVERDOSAGE Topically applied desonide ointment USP, 0.05% can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ).

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Desonide Ointment, 0.05% is supplied in 15 g tubes (NDC 72603-164-01) and 60 g tubes (NDC 72603-164-02). STORAGE Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from freezing.

Adverse event reports

Source: openFDA FAERS
4,961
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: DESONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
62332-485-15 62332-485 Alembic Pharmaceuticals Inc. 1 TUBE in 1 CARTON (62332-485-15) / 15 g in 1 TUBE October 24, 2019
62332-485-60 62332-485 Alembic Pharmaceuticals Inc. 1 TUBE in 1 CARTON (62332-485-60) / 60 g in 1 TUBE October 24, 2019
46708-485-15 46708-485 Alembic Pharmaceuticals Limited 1 TUBE in 1 CARTON (46708-485-15) / 15 g in 1 TUBE March 7, 2025
46708-485-60 46708-485 Alembic Pharmaceuticals Limited 1 TUBE in 1 CARTON (46708-485-60) / 60 g in 1 TUBE March 7, 2025
72603-164-01 72603-164 NORTHSTAR RX LLC 1 TUBE in 1 CARTON (72603-164-01) / 15 g in 1 TUBE September 7, 2023
72603-164-02 72603-164 NORTHSTAR RX LLC 1 TUBE in 1 CARTON (72603-164-02) / 60 g in 1 TUBE September 7, 2023
45802-423-35 45802-423 Padagis Israel Pharmaceuticals Ltd 1 TUBE in 1 CARTON (45802-423-35) / 15 g in 1 TUBE August 22, 2006
45802-423-37 45802-423 Padagis Israel Pharmaceuticals Ltd 1 TUBE in 1 CARTON (45802-423-37) / 60 g in 1 TUBE September 18, 2006
51672-1281-1 51672-1281 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1281-1) / 15 g in 1 TUBE August 3, 1994
51672-1281-3 51672-1281 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1281-3) / 60 g in 1 TUBE August 3, 1994
62332-485 62332-485 Alembic Pharmaceuticals Inc. — October 24, 2019
46708-485 46708-485 Alembic Pharmaceuticals Limited — March 7, 2025
72603-164 72603-164 NORTHSTAR RX LLC — September 7, 2023
45802-423 45802-423 Padagis Israel Pharmaceuticals Ltd — August 22, 2006
51672-1281 51672-1281 Sun Pharmaceutical Industries, Inc. — August 3, 1994

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.